On March 27, 2025, Tyra Biosciences reported its financial results for the fourth quarter and full year ended December 31, 2024. The company concluded 2024 with cash, cash equivalents, and marketable securities totaling $341.4 million, providing a projected cash runway through at least 2027.
For the fourth quarter of 2024, the net loss was $25.571 million, compared to a net loss of $22.830 million for the same period in 2023. Full year 2024 net loss increased to $86.481 million from $69.134 million in 2023, driven by increased research and development expenses.
Research and development expenses for Q4 2024 were $22.180 million, up from $20.677 million in Q4 2023, reflecting continued investment in the clinical pipeline. General and administrative expenses also increased to $7.564 million from $4.957 million year-over-year. The company highlighted that three INDs were cleared by the US FDA for its proprietary small molecules, with TYRA-300 set to be evaluated in three Phase 2 studies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.